Veracyte outlines 10%–13% revenue growth for 2026 while advancing MRD and Prosigna launches [Seeking Alpha]
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Seeking Alpha
Marc Stapley, CEO, reported "Q4 capped off another outstanding year of strong execution for Veracyte with performance across our core businesses that reinforces both the durability of our growth model and the opportunities ahead." He highlighted that total revenue for the fourth quarter was $141 million, up 19% year-over-year, driven by continued strength in the core testing business. Decipher volume grew 21% and Afirma grew 12%, resulting in a combined 16% total testing volume growth. Stapley noted the company provided clinically actionable information to nearly 170,000 patients in the year and has now served over 800,000 patients to date. He stated, "We remain on track to testing our 1 millionth patient later this year." Key 2025 milestones included launching Decipher for metastatic patients, expanding into advanced disease, and generating new clinical evidence across endocrinology and neurology. The pipeline advanced with positive Prosigna outcomes data from the OPTIMA PRELIM
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Veracyte (VCYT) had its price target raised by Needham & Company LLC from $44.00 to $48.00. They now have a "buy" rating on the stock.MarketBeat
- Veracyte Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Veracyte (VCYT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Veracyte: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Veracyte Announces Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire
VCYT
Earnings
- 2/25/26 - Beat
VCYT
Sec Filings
- 2/26/26 - Form 10-K
- 2/25/26 - Form 8-K
- 2/5/26 - Form SCHEDULE
- VCYT's page on the SEC website